Future Science Group
Browse
Supplementary_Table_1_correction[82].docx (162.79 kB)

Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives - Supplementary information

Download (162.79 kB)
Version 2 2023-03-14, 09:34
Version 1 2023-03-10, 12:29
dataset
posted on 2023-03-14, 09:34 authored by Foteini Athanasopoulou, Michail Manolakakis, Santiago Vernia, Nazila Kamaly

Nanomedicines are revolutionizing healthcare as recently demonstrated by the Pfizer/BioNTech and

Moderna COVID-2019 vaccines, with billions of doses administered worldwide in a safe manner.

Nonalcoholic fatty liver disease is the most common noncommunicable chronic liver disease, posing a

major growing challenge to global public health. However, due to unmet diagnostic and therapeutic

needs, there is great interest in the development of novel translational approaches. Nanoparticle-based

approaches offer novel opportunities for efficient and specific drug delivery to liver cells, as a step

toward precision medicines. In this review, the authors highlight recent advances in nanomedicines for

the generation of novel diagnostic and therapeutic tools for nonalcoholic fatty liver disease and related

liver diseases.

History

Usage metrics

    Nanomedicine

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC